1. Home
  2. ADPT vs FORTY Comparison

ADPT vs FORTY Comparison

Compare ADPT & FORTY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Adaptive Biotechnologies Corporation

ADPT

Adaptive Biotechnologies Corporation

HOLD

Current Price

$16.12

Market Cap

2.5B

Sector

Health Care

ML Signal

HOLD

FORTY

Formula Systems (1985) Ltd.

HOLD

Current Price

$167.02

Market Cap

2.6B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
ADPT
FORTY
Founded
2009
1985
Country
United States
Israel
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
EDP Services
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
2.5B
2.6B
IPO Year
2019
1997

Fundamental Metrics

Financial Performance
Metric
ADPT
FORTY
Price
$16.12
$167.02
Analyst Decision
Strong Buy
Analyst Count
10
0
Target Price
$16.60
N/A
AVG Volume (30 Days)
2.8M
589.0
Earning Date
02-10-2026
11-20-2025
Dividend Yield
N/A
1.01%
EPS Growth
N/A
N/A
EPS
N/A
4.53
Revenue
$252,754,000.00
$3,016,039,000.00
Revenue This Year
$50.81
N/A
Revenue Next Year
$1.17
N/A
P/E Ratio
N/A
$36.22
Revenue Growth
42.57
11.45
52 Week Low
$5.96
$80.15
52 Week High
$20.76
$190.56

Technical Indicators

Market Signals
Indicator
ADPT
FORTY
Relative Strength Index (RSI) 47.07 56.38
Support Level $16.05 $170.00
Resistance Level $16.82 $190.56
Average True Range (ATR) 0.60 2.74
MACD -0.03 1.88
Stochastic Oscillator 43.93 55.68

Price Performance

Historical Comparison
ADPT
FORTY

About ADPT Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).

About FORTY Formula Systems (1985) Ltd.

Formula Systems (1985) Ltd is a holding company that, through its subsidiaries, provides information technology services. The company organizes itself into operating segments: The Matrix segment, which generates the majority of revenue, provides software development and existing software expansion services. The Sapiens segment provides software development services for the insurance industry. The Magic Software segment provides vendor management systems and workforce management services, which include accounting and finance, human resources, Michpal, ZAP Group, and Others. The majority of the company's revenue comes from Israel.

Share on Social Networks: